Bausch Health retained an 88 per cent shareholding in the eye care subsidiary after listing the group in 2022. But it planned to offload the remainder of shares by striking a deal with its investors to exchange Bausch Health stock for Bausch + Lomb stock.

Bausch + Lomb shares popped following a report that the eyecare company is considering selling itself, to separate from its heavily indebted parent company Bausch Health Cos.

Bausch + Lomb (BLCO) stock will be in focus as company is exploring a sale to address concerns raised over its separation from Bausch Health (BHC). Read mroe here.

Bausch + Lomb is working with advisers from Goldman Sachs to test interest from possible buyers, the Financial Times reported on Saturday.

Bausch & Lomb (NYSE:BLCO) rose 1.8% in premarket trading after a report about private equity interest in a takeover of the eyecare company. Private equity firms including Blackstone (BX), Advent International,

Company operates a contact lens manufacturing facility in Waterford where approximately 1,500 people are employed.

Eye-care company is working with Goldman Sachs on a deal that would extricate it from its indebted parent, the Financial Times reported.